SF3B1 and breast carcinoma: More recently, studies have identified mutations in SF3B1 in subsets of solid tumours from multiple anatomic sites (see ref 11 for a recent review), including 15% of chronic lymphocytic leukaemias (CLLs) [12], 9.7% of uveal melanomas [13], 4% of pancreatic cancers [14], and 1.8% of breast cancers [4–6,8].